NEW YORK (

TheStreet

) --

Genomic Health

(Nasdaq:

GHDX

) hit a new 52-week high Friday as it traded at $23.74 compared with its previous 52-Week high of $23.72. Genomic Health is changing hands at $23.74 with 16,120 shares traded as of 10:51 a.m. ET. Average volume has been 154,800 shares over the past 30 days.

Genomic Health has a market cap of $662 million and is part of the

health care

sector and

health services

industry. Shares are up 10.3% year to date as of the close of trading on Thursday.

Genomic Health, Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. The company has a P/E ratio of 163.9, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 22.6.

TheStreet Ratings rates Genomic Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full

Genomic Health Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null